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Background
Volume overload and sodium retention in congestive
heart failure (HF) are usually treated with loop diuretics.
However, worsening renal function is frequently
observed and is associated with worse outcomes. Soluble
guanylyl cyclase (sGC) plays an important role in renal
function. Importantly, sGC activation can be impaired
in cardiorenal disease states, which can be due to not
only decreased bioavailability of nitric oxide but also to
heme oxidation or heme loss of sGC, which renders the
enzyme insensitive to NO. Cinaciguat is a novel sGC
activator that stimulates the heme-free, NO-insensitive
form of sGC.
Hypothesis
Cinaciguat unloads the heart and increases renal blood
flow without compromising renal function when added
to furosemide in experimental HF.
Methods
HF was induced in canines (n=13) by tachypacing. On
day 11 of pacing, an acute study was performed under
general anesthesia. The left ureter was catheterized and
the renal artery was equipped with a flow probe. After
equilibration a 30-minute baseline clearance (C1) was
done. After this, animals were assigned to one of two
groups. One group received furosemide (1 mg/kg/h) for
90 minutes, the other group received the same dose of
furosemide plus cinaciguat (0.1 followed by 0.3 µg/kg/
min for 45 minutes each). Two clearances (C2 and C3)
were done from 15-45 and from 60-90 minutes of drug
infusion. After a 30-minute washout a post-infusion
clearance (C4) was done. *p<0.05 between groups.
Results
In the furosemide group, mean arterial pressure was not
changed during drug administration but decreased dur-
ing C4. Cardiac output and systemic and pulmonary
vascular resistances were unchanged. Right atrial, pul-
monary artery, and pulmonary capillary wedge pressures
were reduced during C3 and C4. In the furosemide
+cinaciguat group, mean arterial pressure* and systemic*
and pulmonary* vascular resistances decreased in C2*,
C3*, and C4*. The same was true for right atrial*, pul-
monary artery* and pulmonary capillary wedge pres-
sures*. Cardiac output increased in C2*, C3*, and C4*.
Furosemide alone did not change renal blood flow,
whereas furosemide+cinaciguat increased it in C2, C3*,
and C4. Urine flow and urinary sodium excretion
increased in both groups during C3 and C4 with no dif-
ferences between groups. Glomerular filtration rate
increased with furosemide alone during drug infusion,
while this tended to be the case in the furosemide+cina-
ciguat group, with no differences between groups
(p>0.4).
Conclusion
Cinaciguat when added to furosemide reduces cardiac
preload and afterload and increases renal blood flow
when compared to furosemide alone. Importantly, GFR
and sodium excretion were not negatively affected by
cinaciguat, despite the reduction in mean arterial pres-
sure. It remains to be established whether these
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promising findings can translate into improved renal
outcomes in patients with HF.
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